DURECT Corp (DRRX)-医療機器分野:企業M&A・提携分析

◆英語タイトル:DURECT Corp (DRRX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8013836
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
DURECT Corp (Durect) is a specialty pharmaceutical company. It carries out the development of pharmaceutical systems based on its proprietary drug delivery technology platforms to treat chronic debilitating diseases. It also undertakes the development of biotechnology products. The company’s major products include Alzet, an osmotic pump; and Lactel, a biodegradable polymer. The company’s product pipeline comprises DUR-928 indicated for treatment of acute organ injuries and metabolic/lipid disorders; Remoxy, indicated for chronic pain; Posimir, indicated for post-operative pain; Eladur, indicated for post herpetic neuralgia; Oradur, indicated for chronic pain and attention deficit hyperactivity disorder; and Relday, indicated for Schizophrenia and bipolar disorder. Durect’s major drug delivery technology platforms include Saber, Cloud, Oradur and Transdur. The company operates in the US, Europe, Japan and other countries. Durect is headquartered in California, the US.

DURECT Corp (DRRX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
DURECT Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
DURECT Corp, Medical Equipment Deals By Type, 2011 to YTD 2017 6
DURECT Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
DURECT Corp, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
DURECT Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
DURECT Corp, Medical Equipment, Deal Details 10
Partnerships 10
Durect Enters into Licensing Agreement with Santen Pharma 10
Durect Enters Into Licensing Agreement with Virginia Commonwealth University Intellectual Property Foundation 11
Equity Offering 12
Durect Files Registration Statement For Public Offering Of Securities For US$100.9 Million 12
Durect Files Registration Statement For Public Offering Of Common Stock For Up To US$25 Million 13
Durect Completes Public Offering Of Shares For US$11.5 Million 14
Durect Completes Public Offering Of Shares For US$13 Million 15
DURECT Corp – Key Competitors 16
DURECT Corp – Key Employees 17
DURECT Corp – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Financial Announcements 19
Nov 01, 2017: DURECT Announces Third Quarter 2017 Financial Results and Provides Corporate Update 19
Aug 08, 2017: DURECT Announces Second Quarter 2017 Financial Results and Provides Corporate Update 21
May 10, 2017: DURECT Announces First Quarter 2017 Financial Results and Provides Corporate Update 23
Mar 14, 2017: DURECT Announces Fourth Quarter and Full Year 2016 Financial Results and Update of Programs 25
Oct 31, 2016: DURECT Announces Third Quarter 2016 Financial Results and Update of Programs 27
Aug 01, 2016: DURECT Announces Second Quarter 2016 Financial Results and Update of Programs 29
May 05, 2016: DURECT Announces First Quarter 2016 Financial Results and Update of Programs 31
Feb 29, 2016: DURECT Announces Fourth Quarter 2015 Financial Results and Update of Programs 33
Corporate Communications 35
Sep 20, 2017: DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
DURECT Corp, Medical Equipment, Key Facts, 2016 2
DURECT Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
DURECT Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
DURECT Corp, Medical Equipment Deals By Type, 2011 to YTD 2017 6
DURECT Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
DURECT Corp, Deals By Market, 2011 to YTD 2017 8
DURECT Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Durect Enters into Licensing Agreement with Santen Pharma 10
Durect Enters Into Licensing Agreement with Virginia Commonwealth University Intellectual Property Foundation 11
Durect Files Registration Statement For Public Offering Of Securities For US$100.9 Million 12
Durect Files Registration Statement For Public Offering Of Common Stock For Up To US$25 Million 13
Durect Completes Public Offering Of Shares For US$11.5 Million 14
Durect Completes Public Offering Of Shares For US$13 Million 15
DURECT Corp, Key Competitors 16
DURECT Corp, Key Employees 17

★海外企業調査レポート[DURECT Corp (DRRX)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sony Corporation:企業の戦略・SWOT・財務情報
    Sony Corporation - Strategy, SWOT and Corporate Finance Report Summary Sony Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Shuwen Biotech Co Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Shuwen Biotech Co Ltd (Shuwen Biotech) is a medical equipment company. The company develops diagnostic products and services for disease prevention, diagnosis and personalized medicine. It offers in-vitro diagnostic (IVD) kits for oncology and pregnancy-related conditions. Shuwen Biotech dev …
  • RRB Energy Ltd:企業の戦略的SWOT分析
    RRB Energy Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • NTN Corporation:企業の戦略・SWOT・財務分析
    NTN Corporation - Strategy, SWOT and Corporate Finance Report Summary NTN Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Omaxe Ltd:企業の戦略・SWOT・財務情報
    Omaxe Ltd - Strategy, SWOT and Corporate Finance Report Summary Omaxe Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Greenleaf Power LLC:電力:M&Aディール及び事業提携情報
    Summary Greenleaf Power LLC (Greenleaf Power) is a provider of renewable energy services in North America. The company acquires and operates base-load biomass plants to generate electricity. It collects residual biomass material from agricultural, construction, demolition, landfill, and timber indus …
  • Pierrel Spa (PRL):企業の財務・戦略的SWOT分析
    Pierrel Spa (PRL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • NeoTract Inc:医療機器:M&Aディール及び事業提携情報
    Summary NeoTract Inc (NeoTract) is a medical device company that designs and develops minimally invasive devices for use in the field of urology. The company’s urolift system is designed to treat lower urinary tract symptoms caused by benign prostatic hyperplasia. It partners with its customers to i …
  • Societe Nationale d’Electrolyse et de Petrochimie SA (SNP):企業の財務・戦略的SWOT分析
    Societe Nationale d'Electrolyse et de Petrochimie SA (SNP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the compa …
  • Umicore SA:企業の戦略・SWOT・財務情報
    Umicore SA - Strategy, SWOT and Corporate Finance Report Summary Umicore SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Advanced Technology Company (ATC):企業の財務・戦略的SWOT分析
    Advanced Technology Company (ATC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • W. L. Gore & Associates, Inc.:企業の戦略・SWOT・財務情報
    W. L. Gore & Associates, Inc. - Strategy, SWOT and Corporate Finance Report Summary W. L. Gore & Associates, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • SREI Infrastructure Finance Ltd:企業のM&A・事業提携・投資動向
    SREI Infrastructure Finance Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's SREI Infrastructure Finance Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Varta Microbattery GmbH:企業の戦略的SWOT分析
    Varta Microbattery GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Bicycle Therapeutics Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Bicycle Therapeutics Ltd (Bicycle Therapeutics) is a biotechnology company which develops bicyclic peptides (Medicines) for the treatment of cancers and other debilitating diseases. The company's proprietary bicyclic peptide technology enables systematic cyclisation of peptides and helps to …
  • Dottikon ES Holding AG (DESN):製薬・医療:M&Aディール及び事業提携情報
    Summary Dottikon ES Holding AG (Dottikon) manufactures and commercializes active pharmaceutical ingredients (APIs), performance chemicals and intermediates for chemical and pharmaceutical industries. The company finds novel uses for hazardous reactions and continuous processing that facilitate the r …
  • EPI Ingredients:企業の戦略・SWOT・財務情報
    EPI Ingredients - Strategy, SWOT and Corporate Finance Report Summary EPI Ingredients - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • DesignMedix Inc-製薬・医療分野:企業M&A・提携分析
    Summary DesignMedix Inc (DesignMedix) is a biotechnology company that develop drugs to overcome drug resistance in multiple diseases including malaria and diarrhea. The company focuses on the development of malaria cure drugs, malaria preventive drugs and anti-bacterial drugs. Its malaria cure drugs …
  • Tianda Pharmaceuticals Ltd (455):製薬・医療:M&Aディール及び事業提携情報
    Summary Tianda Pharmaceuticals Ltd (Tianda Pharma), a subsidiary of Tianda Group Ltd, is a healthcare supplement product manufacturer that researches, develops, manufactures and markets biotechnology, pharmaceutical and health care products. The company provides products covering various therapeutic …
  • Liquefied Natural Gas Ltd (LNG):石油・ガス:M&Aディール及び事業提携情報
    Summary Liquefied Natural Gas Ltd (LNGL) is an oil and gas company that constructs, plans, manages, and operates liquefied natural gas plants. The company uses the optimized single mixed refrigerant process to develop liquefied natural gas. Its optimized single mixed refrigerant process also provide …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆